It’s Formulary Season, and Early Analyses Suggest Big Changes in How PBMs Approach Biosims

This Congressional Budget Office report on the Center for Medicare & Medicaid Innovation makes for fascinating reading. As background, CMMI was created as part of the Affordable Care Act, designed

Well, this is a fitting end to a wild week. We now have the 15 medicines that will go through the next round of price-setting “negotiations” with CMS. Here are

Congrats to patient advocate/CEO John Crowley, who will be taking over as the CEO of the Biotechnology Innovation Organization. No one knows the stakes of drug development better than John,